Search Results

The Canadian Medical Isotope Ecosystem will support the development, production, advancement and distribution of isotopes, and position Canada as an international medical isotope powerhouse

On November 16, the Canadian Medical Isotope Ecosystem (CMIE) - an initiative co-led by TRIUMF Innovations and the Centre for Probe Development and Commercialization

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada’s particle accelerator centre, announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225.

CDRD, Canada’s life sciences venture, TRIUMF, the country’s national particle accelerator centre, and TRIUMF Innovations, the centre’s commercialization arm have joined forces to advance and commercialize promising research in the field of novel radiopharmaceuticals

BVI® through its PhysIOL subsidiary, the pioneer of trifocal technology, announces today the European launch of FineVision Triumf EDOF trifocal presbyopia correcting intraocular lens for patients undergoing cataract surgery.

BWXT Medical Ltd. has submitted a Drug Master File to the U.S. Drug and Food Administration for No Carrier Added Actinium-225 Active Pharmaceutical Ingredient.

ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use. For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the Centre for Probe Development and Commercialization

ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.

CDRD LifeSciences BC, TRIUMF Innovations and BIOTECanada – are hosting an event today to build support and encourage action and agreement that will advance recommendations from The Government of Canada’s Health and Biosciences Economic Strategy Table Report.

BWXT Medical Ltd. and Fusion Pharmaceuticals Inc. announced that the companies have entered into an agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.